Older corneas "just as good" for transplant

Article

Corneas from donors up to the age of 75 are suitable for transplantation, according to a study published in the April 2008 issue of Ophthalmology.

Corneas from donors up to the age of 75 are suitable for transplantation, according to a study published in the April 2008 issue of Ophthalmology.

Edward Holland, MD of the University of Rochester Medical Center, US and colleagues on the Cornea Donor Study conducted the multicentre prospective, double-masked, controlled five-year trial of 1090 subjects to establish a comparison between graft survival in tissue from donors under the age of 65 with tissue taken from older donors.

Probability of graft failure, defined as three months’ consecutive impact on vision due to corneal opacity or regraft requirement, was 14% across both donor age groups (<66 years and ≥66 years). There was no statistically significant correlation between donor age and graft failure or survival, nor was there a statistically significant difference between age groups over the causes of graft failure.

Thus the researchers concluded that donor age is not a significant variable in graft failure. Dr Holland estimates that this will increase the pool of available donor corneas by 25–30%.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.